![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
November 21, 2025
The latest clinical trial findings in follicular lymphoma, prostate cancer, precision medicine, symptom science, and patient -reported outcomes
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022
This randomized phase 2 trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
December 14, 2020
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction